Nab-Paclitaxel Subgroup Analyses in Non-Small Cell Lung Cancer

In this segment, panelists discuss histology and age subgroup analyses from the phase III CA031 study that explored frontline nab-paclitaxel plus carboplatin in patients with non-small cell lung cancer.

To view more from this discussion, visit http://www.onclive.com/peer-exchange/nsclc-needs

• categorie